Lamotrigine blocks the initiation and expression of repeated high-dose methamphetamine-induced prepulse inhibition deficit in rats.
Our group developed a new psychostimulant animal model reflecting some clinical aspects of schizophrenia better than the conventional model does. In this model, long-lasting prepulse inhibition (PPI) deficit at the basement state is induced via repeated administration of methamphetamine (METH, 2.5mg/kg) without challenge injection of this psychostimulant. This study elucidates the effects of lamotrigine (LTG, 30mg/kg) on the initiation and expression of a steady-state PPI deficit induced by the repeated METH administration. We assessed the effect of coadministration of LTG and METH on the initiation of PPI deficit. The LTG was injected 120min after each METH injection for 5 times on every alternate day and for an additional 5 times every day, amounting to a total of 10 times. After 11-13 days of the withdrawal period, we measured PPI using the SR-LAB system. Using other animals after 20min of LTG injection, we subsequently examined the effect of a single injection of LTG on the expression of PPI deficit caused by the repeated METH administration. The LTG blocked the initiation of PPI deficit induced by the repeated METH administration at 68dB of prepulse intensity, but had no effect on the startle amplitude. The LTG prevented the initiation and expression of neuroplastic PPI deficit detected at the baseline state without any METH challenge injection, which was induced by the repeated administration of this psychostimulant. Results suggest that LTG is useful for blocking progressive deterioration of neurocognitive function and recovering the neurocognitive deficit in schizophrenia.
Nakato
Yasuya
Y
Department of Psychiatry, Hokkaido University Graduate School of Medicine, North 15, West 7, Sapporo, Hokkaido 060-8638, Japan. nakatou@med.hokudai.ac.jp
Abekawa
Tomohiro
T
Ito
Koki
K
Inoue
Takeshi
T
Koyama
Tsukasa
T
D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology*; D000697:Central Nervous System Stimulants / Q000633:toxicity; D004195:Disease Models, Animal; D000077213:Lamotrigine; D008297:Male; D008694:Methamphetamine / Q000633:toxicity; D009433:Neural Inhibition / Q000187:drug effects*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013216:Reflex, Startle / Q000187:drug effects / Q000502:physiology; D012559:Schizophrenia / Q000139:chemically induced / Q000503:physiopathology*; D014227:Triazines / Q000494:pharmacology*
D000927:Anticonvulsants; D000697:Central Nervous System Stimulants; D014227:Triazines; D008694:Methamphetamine; D000077213:Lamotrigine